Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2013

Open Access 01-12-2013 | Research

Behçet’s disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity

Authors: Ihosvany Fernández-Bello, Francisco J López-Longo, Elena G Arias-Salgado, Víctor Jiménez-Yuste, Nora V Butta

Published in: Orphanet Journal of Rare Diseases | Issue 1/2013

Login to get access

Abstract

Background

Behçet disease (BD) is associated with a prothrombotic state of unknown origin that may lead to life-threatening events. Calibrated Automated Thrombogram (CAT) and Rotational Thromboelastometry (ROTEM) are two global haemostasis assays that may reveal new insights into the physiopathological mechanisms of the disease and its procoagulant condition.

Methods

23 BD patients who had no signs or symptoms of current thrombosis and 33 age- and sex-matched controls were included in the study. We performed ROTEM and CAT tests and assessed erythrocyte count, platelet count, platelet contribution to clot formation and plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor type 1 (PAI-1), fibrinogen, C-reactive protein (CRP), thrombin-antithrombin III complex (TAT), D-dimer and E-selectin (ES).

Results

Both ROTEM and CAT tests showed a hypercoagulable state in the BD patients. Plasma levels of PAI-1, fibrinogen, TAT, CRP and ES were significantly increased in this group compared to controls. The disease activity (DA) was significantly correlated with levels of ES and the maximum clot firmness, and this last one, in turn, correlated with rising levels of ES, PAI-1, CRP and fibrinogen. CAT parameters did not correlate with DA or ES.

Conclusions

Both ROTEM and CAT tests reveal that patients with BD have a procoagulant state even in the absence of thrombosis. ROTEM test indicates that increased levels of fibrinogen and PAI-1 may be involved in the prothrombotic state of this pathology, while platelets do not significantly contribute. Moreover, CAT assay demonstrate that plasma from BD patients is able to generate more thrombin than controls in response to the same stimulus and that this effect is independent of the DA and the endothelial impairment suggesting the involvement of another factor in the hypercoagulable state observed in BD patients. This study also shows that endothelium activation/damage may be a contributing factor in both the procoagulant and clinical conditions of BD, as shown by the direct correlation between ES levels, ROTEM parameters and DA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sakane T, Takeno M, Suzuki N, Inaba G: Behcet's disease. N Engl J Med. 1999, 341: 1284-1291. 10.1056/NEJM199910213411707.PubMedCrossRef Sakane T, Takeno M, Suzuki N, Inaba G: Behcet's disease. N Engl J Med. 1999, 341: 1284-1291. 10.1056/NEJM199910213411707.PubMedCrossRef
2.
go back to reference Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, Batman F, Kansu T, Balkanci F, Akkaya S: Vascular involvement in Behcet's disease. J Rheumatol. 1992, 19: 402-410.PubMed Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, Batman F, Kansu T, Balkanci F, Akkaya S: Vascular involvement in Behcet's disease. J Rheumatol. 1992, 19: 402-410.PubMed
3.
go back to reference Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M, Tzellos T, Zouboulis CC, Akhlagi M, International Team for the Revision of the International Criteria for Behcet's D: The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2013, 10.1111/jdv.12107. Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M, Tzellos T, Zouboulis CC, Akhlagi M, International Team for the Revision of the International Criteria for Behcet's D: The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2013, 10.1111/jdv.12107.
4.
go back to reference Altenburg A, Mahr A, Maldini C, Kneifel CE, Krause L, Kotter I, Stache T, Bonitsis NG, Zouboulis CC: Epidemiology and clinical aspects of Adamantiades-Behcet disease in Gemany. Current data. Der Ophthalmologe. 2012, 109: 531-541. 10.1007/s00347-012-2601-4.PubMedCrossRef Altenburg A, Mahr A, Maldini C, Kneifel CE, Krause L, Kotter I, Stache T, Bonitsis NG, Zouboulis CC: Epidemiology and clinical aspects of Adamantiades-Behcet disease in Gemany. Current data. Der Ophthalmologe. 2012, 109: 531-541. 10.1007/s00347-012-2601-4.PubMedCrossRef
5.
go back to reference Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990, 335: 1078-1080. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990, 335: 1078-1080.
6.
go back to reference Haznedaroglu IC, Ozcebe OI, Ozdemir O, Celik I, Dundar SV, Kirazli S: Impaired haemostatic kinetics and endothelial function in Behcet's disease. J Intern Med. 1996, 240: 181-187. 10.1046/j.1365-2796.1996.396853000.x.PubMedCrossRef Haznedaroglu IC, Ozcebe OI, Ozdemir O, Celik I, Dundar SV, Kirazli S: Impaired haemostatic kinetics and endothelial function in Behcet's disease. J Intern Med. 1996, 240: 181-187. 10.1046/j.1365-2796.1996.396853000.x.PubMedCrossRef
7.
go back to reference Chambers JC, Haskard DO, Kooner JS: Vascular endothelial function and oxidative stress mechanisms in patients with Behcet's syndrome. J Am Coll Cardiol. 2001, 37: 517-520. 10.1016/S0735-1097(00)01137-2.PubMedCrossRef Chambers JC, Haskard DO, Kooner JS: Vascular endothelial function and oxidative stress mechanisms in patients with Behcet's syndrome. J Am Coll Cardiol. 2001, 37: 517-520. 10.1016/S0735-1097(00)01137-2.PubMedCrossRef
8.
go back to reference Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, Lopez-Soto A, Cervera R, Ordinas A, Ingelmo M, Reverter JC: Vascular involvement in Behcet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002, 112: 37-43. 10.1016/S0002-9343(01)01048-8.PubMedCrossRef Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, Lopez-Soto A, Cervera R, Ordinas A, Ingelmo M, Reverter JC: Vascular involvement in Behcet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002, 112: 37-43. 10.1016/S0002-9343(01)01048-8.PubMedCrossRef
9.
go back to reference Aitchison R, Chu P, Cater DR, Harris RJ, Powell RJ: Defective fibrinolysis in Behcet's syndrome: significance and possible mechanisms. Ann Rheum Dis. 1989, 48: 590-593. 10.1136/ard.48.7.590.PubMedCentralPubMedCrossRef Aitchison R, Chu P, Cater DR, Harris RJ, Powell RJ: Defective fibrinolysis in Behcet's syndrome: significance and possible mechanisms. Ann Rheum Dis. 1989, 48: 590-593. 10.1136/ard.48.7.590.PubMedCentralPubMedCrossRef
10.
go back to reference Ricart JM, Ramon LA, Vaya A, Espana F, Santaolaria ML, Todoli J, Castello R, Fontcuberta J, Estelles A: Fibrinolytic inhibitor levels and polymorphisms in Behcet disease and their association with thrombosis. Br J Haematol. 2008, 141: 716-719. 10.1111/j.1365-2141.2008.07078.x.PubMedCrossRef Ricart JM, Ramon LA, Vaya A, Espana F, Santaolaria ML, Todoli J, Castello R, Fontcuberta J, Estelles A: Fibrinolytic inhibitor levels and polymorphisms in Behcet disease and their association with thrombosis. Br J Haematol. 2008, 141: 716-719. 10.1111/j.1365-2141.2008.07078.x.PubMedCrossRef
11.
go back to reference Yurdakul S, Hekim N, Soysal T, Fresko I, Bavunoglu I, Ozbakir F, Tabak F, Melikoglu M, Hamuryudan V, Yazici H: Fibrinolytic activity and d-dimer levels in Behcet's syndrome. Clin Exp Rheumatol. 2005, 23: S53-S58.PubMed Yurdakul S, Hekim N, Soysal T, Fresko I, Bavunoglu I, Ozbakir F, Tabak F, Melikoglu M, Hamuryudan V, Yazici H: Fibrinolytic activity and d-dimer levels in Behcet's syndrome. Clin Exp Rheumatol. 2005, 23: S53-S58.PubMed
12.
go back to reference Wilson AP, Efthimiou J, Betteridge DJ: Decreased prostacyclin sensitivity of platelets in patients with Behcet's syndrome. Eur J Clin Invest. 1988, 18: 410-414. 10.1111/j.1365-2362.1988.tb01032.x.PubMedCrossRef Wilson AP, Efthimiou J, Betteridge DJ: Decreased prostacyclin sensitivity of platelets in patients with Behcet's syndrome. Eur J Clin Invest. 1988, 18: 410-414. 10.1111/j.1365-2362.1988.tb01032.x.PubMedCrossRef
13.
go back to reference Akar S, Ozcan MA, Ates H, Gurler O, Alacacioglu I, Ozsan GH, Akkoc N, Ozkan S, Demirkan F, Onen F: Circulated activated platelets and increased platelet reactivity in patients with Behcet's disease. Clin Appl Thromb/Hemost. 2006, 12: 451-457. 10.1177/1076029606293430.CrossRef Akar S, Ozcan MA, Ates H, Gurler O, Alacacioglu I, Ozsan GH, Akkoc N, Ozkan S, Demirkan F, Onen F: Circulated activated platelets and increased platelet reactivity in patients with Behcet's disease. Clin Appl Thromb/Hemost. 2006, 12: 451-457. 10.1177/1076029606293430.CrossRef
14.
go back to reference Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S: Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003, 33: 4-15. 10.1159/000071636.PubMedCrossRef Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S: Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003, 33: 4-15. 10.1159/000071636.PubMedCrossRef
15.
go back to reference Luddington RJ: Thrombelastography/thromboelastometry. Clin Lab Haematol. 2005, 27: 81-90. 10.1111/j.1365-2257.2005.00681.x.PubMedCrossRef Luddington RJ: Thrombelastography/thromboelastometry. Clin Lab Haematol. 2005, 27: 81-90. 10.1111/j.1365-2257.2005.00681.x.PubMedCrossRef
16.
go back to reference van Veen JJ, Gatt A, Makris M: Thrombin generation testing in routine clinical practice: are we there yet?. Br J Haematol. 2008, 142: 889-903. 10.1111/j.1365-2141.2008.07267.x.PubMedCrossRef van Veen JJ, Gatt A, Makris M: Thrombin generation testing in routine clinical practice: are we there yet?. Br J Haematol. 2008, 142: 889-903. 10.1111/j.1365-2141.2008.07267.x.PubMedCrossRef
17.
go back to reference Ten Cate H: Thrombin generation in clinical conditions. Thromb Res. 2012, 129: 367-370. 10.1016/j.thromres.2011.10.017.PubMedCrossRef Ten Cate H: Thrombin generation in clinical conditions. Thromb Res. 2012, 129: 367-370. 10.1016/j.thromres.2011.10.017.PubMedCrossRef
18.
go back to reference Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ: Behcet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999, 38: 728-733. 10.1093/rheumatology/38.8.728.CrossRef Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ: Behcet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999, 38: 728-733. 10.1093/rheumatology/38.8.728.CrossRef
19.
go back to reference Hampton KK, Chamberlain MA, Menon DK, Davies JA: Coagulation and fibrinolytic activity in Behcet's disease. Thromb Haemost. 1991, 66: 292-294.PubMed Hampton KK, Chamberlain MA, Menon DK, Davies JA: Coagulation and fibrinolytic activity in Behcet's disease. Thromb Haemost. 1991, 66: 292-294.PubMed
20.
go back to reference Lee YJ, Kang SW, Yang JI, Choi YM, Sheen D, Lee EB, Choi SW, Song YW: Coagulation parameters and plasma total homocysteine levels in Behcet's disease. Thromb Res. 2002, 106: 19-24. 10.1016/S0049-3848(02)00085-3.PubMedCrossRef Lee YJ, Kang SW, Yang JI, Choi YM, Sheen D, Lee EB, Choi SW, Song YW: Coagulation parameters and plasma total homocysteine levels in Behcet's disease. Thromb Res. 2002, 106: 19-24. 10.1016/S0049-3848(02)00085-3.PubMedCrossRef
21.
go back to reference Probst K, Fijnheer R, Rothova A: Endothelial cell activation and hypercoagulability in ocular Behcet's disease. Am J Ophthalmol. 2004, 137: 850-857. 10.1016/j.ajo.2003.12.010.PubMedCrossRef Probst K, Fijnheer R, Rothova A: Endothelial cell activation and hypercoagulability in ocular Behcet's disease. Am J Ophthalmol. 2004, 137: 850-857. 10.1016/j.ajo.2003.12.010.PubMedCrossRef
22.
go back to reference Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC: Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology (Baltimore, Md). 1990, 12: 1179-1186. 10.1002/hep.1840120517.CrossRef Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC: Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology (Baltimore, Md). 1990, 12: 1179-1186. 10.1002/hep.1840120517.CrossRef
23.
go back to reference Lang T, Johanning K, Metzler H, Piepenbrock S, Solomon C, Rahe-Meyer N, Tanaka KA: The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg. 2009, 108: 751-758. 10.1213/ane.0b013e3181966675.PubMedCrossRef Lang T, Johanning K, Metzler H, Piepenbrock S, Solomon C, Rahe-Meyer N, Tanaka KA: The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg. 2009, 108: 751-758. 10.1213/ane.0b013e3181966675.PubMedCrossRef
24.
go back to reference Jacquemin B, Antoniades C, Nyberg F, Plana E, Muller M, Greven S, Salomaa V, Sunyer J, Bellander T, Chalamandaris AG: Common genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. J Am Coll Cardiol. 2008, 52: 941-952. 10.1016/j.jacc.2008.06.016.PubMedCrossRef Jacquemin B, Antoniades C, Nyberg F, Plana E, Muller M, Greven S, Salomaa V, Sunyer J, Bellander T, Chalamandaris AG: Common genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. J Am Coll Cardiol. 2008, 52: 941-952. 10.1016/j.jacc.2008.06.016.PubMedCrossRef
25.
go back to reference Dielis AW, Castoldi E, Spronk HM, van Oerle R, Hamulyak K, Ten Cate H, Rosing J: Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost. 2008, 6: 125-131.PubMedCrossRef Dielis AW, Castoldi E, Spronk HM, van Oerle R, Hamulyak K, Ten Cate H, Rosing J: Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost. 2008, 6: 125-131.PubMedCrossRef
26.
go back to reference Lovely RS, Boshkov LK, Marzec UM, Hanson SR, Farrell DH: Fibrinogen gamma' chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. Br J Haematol. 2007, 139: 494-503. 10.1111/j.1365-2141.2007.06825.x.PubMedCrossRef Lovely RS, Boshkov LK, Marzec UM, Hanson SR, Farrell DH: Fibrinogen gamma' chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. Br J Haematol. 2007, 139: 494-503. 10.1111/j.1365-2141.2007.06825.x.PubMedCrossRef
27.
go back to reference Mosesson MW: Update on antithrombin I (fibrin). Thromb Haemost. 2007, 98: 105-108.PubMed Mosesson MW: Update on antithrombin I (fibrin). Thromb Haemost. 2007, 98: 105-108.PubMed
28.
go back to reference Hemker HC, Al Dieri R, De Smedt E, Beguin S: Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006, 96: 553-561.PubMed Hemker HC, Al Dieri R, De Smedt E, Beguin S: Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006, 96: 553-561.PubMed
29.
go back to reference Regnault V, Beguin S, Wahl D, de Maistre E, Coenraad Hemker H, Lecompte T: Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost. 2003, 89: 208-212.PubMed Regnault V, Beguin S, Wahl D, de Maistre E, Coenraad Hemker H, Lecompte T: Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost. 2003, 89: 208-212.PubMed
30.
go back to reference Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990, 86: 385-391. 10.1172/JCI114723.PubMedCentralPubMedCrossRef Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990, 86: 385-391. 10.1172/JCI114723.PubMedCentralPubMedCrossRef
31.
go back to reference Bowbrick VA, Mikhailidis DP, Stansby G: Influence of platelet count and activity on thromboelastography parameters. Platelets. 2003, 14: 219-224. 10.1080/0953710031000118849.PubMedCrossRef Bowbrick VA, Mikhailidis DP, Stansby G: Influence of platelet count and activity on thromboelastography parameters. Platelets. 2003, 14: 219-224. 10.1080/0953710031000118849.PubMedCrossRef
32.
go back to reference Martinez M, Ricart JM, Ruiz-Aja S, Rus A, Todoli J, Calvo J, Vaya A: Platelet activation and red blood cell phosphatidylserine exposure evaluated by flow cytometry in patients with Behcet's disease: are they related to thrombotic events?. Pathophysiol Haemost Thromb. 2007, 36: 18-22. 10.1159/000112635.PubMedCrossRef Martinez M, Ricart JM, Ruiz-Aja S, Rus A, Todoli J, Calvo J, Vaya A: Platelet activation and red blood cell phosphatidylserine exposure evaluated by flow cytometry in patients with Behcet's disease: are they related to thrombotic events?. Pathophysiol Haemost Thromb. 2007, 36: 18-22. 10.1159/000112635.PubMedCrossRef
33.
go back to reference Fernandez Bello I, Alvarez MT, Lopez-Longo FJ, Arias-Salgado EG, Martin M, Jimenez-Yuste V, Rodriguez de la Rua A, Butta NV: Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behcet disease patients. Thromb Haemost. 2012, 107: 88-98.PubMedCrossRef Fernandez Bello I, Alvarez MT, Lopez-Longo FJ, Arias-Salgado EG, Martin M, Jimenez-Yuste V, Rodriguez de la Rua A, Butta NV: Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behcet disease patients. Thromb Haemost. 2012, 107: 88-98.PubMedCrossRef
34.
go back to reference Spiezia L, Radu C, Marchioro P, Bertini D, Rossetto V, Castelli M, Pagnan A, Sorensen B, Simioni P: Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients. Thromb Haemost. 2008, 100: 1106-1110.PubMed Spiezia L, Radu C, Marchioro P, Bertini D, Rossetto V, Castelli M, Pagnan A, Sorensen B, Simioni P: Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients. Thromb Haemost. 2008, 100: 1106-1110.PubMed
35.
go back to reference Carmeliet P, Collen D: Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis. Curr Opin Lipidol. 1997, 8: 118-125. 10.1097/00041433-199704000-00010.PubMedCrossRef Carmeliet P, Collen D: Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis. Curr Opin Lipidol. 1997, 8: 118-125. 10.1097/00041433-199704000-00010.PubMedCrossRef
36.
go back to reference Demirer S, Sengul N, Yerdel MA, Tuzuner A, Ulus AT, Gurler A, Bergqvist D, Siegbahn A, Karacagil S: Haemostasis in patients with Behcet's disease. Eur J Vasc Endovasc Surg. 2000, 19: 570-574. 10.1053/ejvs.2000.1091.PubMedCrossRef Demirer S, Sengul N, Yerdel MA, Tuzuner A, Ulus AT, Gurler A, Bergqvist D, Siegbahn A, Karacagil S: Haemostasis in patients with Behcet's disease. Eur J Vasc Endovasc Surg. 2000, 19: 570-574. 10.1053/ejvs.2000.1091.PubMedCrossRef
37.
go back to reference Ozoran K, Dugun N, Gurler A, Tutkak H, Tokgoz G: Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behcet's disease. Scand J Rheumatol. 1995, 24: 376-382. 10.3109/03009749509095184.PubMedCrossRef Ozoran K, Dugun N, Gurler A, Tutkak H, Tokgoz G: Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behcet's disease. Scand J Rheumatol. 1995, 24: 376-382. 10.3109/03009749509095184.PubMedCrossRef
38.
go back to reference Shang H, Ye JJ, Ji M, Wang FF, Zhu YY, Qi XM: Anticoagulant and Fibrinolytic Disorders in Patients with Behcet's Disease and Recurrent Aphthous Ulcer. Chin J Physiol. 2011, 54: 235-240.PubMedCrossRef Shang H, Ye JJ, Ji M, Wang FF, Zhu YY, Qi XM: Anticoagulant and Fibrinolytic Disorders in Patients with Behcet's Disease and Recurrent Aphthous Ulcer. Chin J Physiol. 2011, 54: 235-240.PubMedCrossRef
39.
go back to reference Juhan-Vague I, Alessi MC, Mavri A, Morange PE: Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003, 1: 1575-1579. 10.1046/j.1538-7836.2003.00279.x.PubMedCrossRef Juhan-Vague I, Alessi MC, Mavri A, Morange PE: Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003, 1: 1575-1579. 10.1046/j.1538-7836.2003.00279.x.PubMedCrossRef
40.
go back to reference Pircher J, Merkle M, Wornle M, Ribeiro A, Czermak T, Stampnik Y, Mannell H, Niemeyer M, Vielhauer V, Krotz F: Prothrombotic effects of tumor necrosis factor alpha in vivo are amplified by the absence of TNF-alpha receptor subtype 1 and require TNF-alpha receptor subtype 2. Arthritis Res Ther. 2012, 14: R225-10.1186/ar4064.PubMedCentralPubMedCrossRef Pircher J, Merkle M, Wornle M, Ribeiro A, Czermak T, Stampnik Y, Mannell H, Niemeyer M, Vielhauer V, Krotz F: Prothrombotic effects of tumor necrosis factor alpha in vivo are amplified by the absence of TNF-alpha receptor subtype 1 and require TNF-alpha receptor subtype 2. Arthritis Res Ther. 2012, 14: R225-10.1186/ar4064.PubMedCentralPubMedCrossRef
41.
go back to reference Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S: Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood. 2004, 104: 3943-3948. 10.1182/blood-2004-04-1439.PubMedCrossRef Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S: Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood. 2004, 104: 3943-3948. 10.1182/blood-2004-04-1439.PubMedCrossRef
42.
go back to reference Nylander M, Osman A, Ramstrom S, Aklint E, Larsson A, Lindahl TL: The role of thrombin receptors PAR1 and PAR4 for PAI-1 storage, synthesis and secretion by human platelets. Thromb Res. 2012, 129: e51-e58. 10.1016/j.thromres.2011.12.021.PubMedCrossRef Nylander M, Osman A, Ramstrom S, Aklint E, Larsson A, Lindahl TL: The role of thrombin receptors PAR1 and PAR4 for PAI-1 storage, synthesis and secretion by human platelets. Thromb Res. 2012, 129: e51-e58. 10.1016/j.thromres.2011.12.021.PubMedCrossRef
43.
go back to reference Wang J, Li J, Liu Q: Association between platelet activation and fibrinolysis in acute stroke patients. Neurosci Lett. 2005, 384: 305-309. 10.1016/j.neulet.2005.04.090.PubMedCrossRef Wang J, Li J, Liu Q: Association between platelet activation and fibrinolysis in acute stroke patients. Neurosci Lett. 2005, 384: 305-309. 10.1016/j.neulet.2005.04.090.PubMedCrossRef
44.
go back to reference Pihusch V, Pihusch M, Penovici M, Kolb HJ, Hiller E, Pihusch R: Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation. Thromb Res. 2005, 116: 233-240. 10.1016/j.thromres.2004.12.010.PubMedCrossRef Pihusch V, Pihusch M, Penovici M, Kolb HJ, Hiller E, Pihusch R: Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation. Thromb Res. 2005, 116: 233-240. 10.1016/j.thromres.2004.12.010.PubMedCrossRef
45.
go back to reference Fujii S, Hopkins WE, Sobel BE: Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis. Circulation. 1991, 83: 645-651. 10.1161/01.CIR.83.2.645.PubMedCrossRef Fujii S, Hopkins WE, Sobel BE: Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis. Circulation. 1991, 83: 645-651. 10.1161/01.CIR.83.2.645.PubMedCrossRef
46.
go back to reference Slivka SR, Loskutoff DJ: Platelets stimulate endothelial cells to synthesize type 1 plasminogen activator inhibitor. Evaluation of the role of transforming growth factor beta. Blood. 1991, 77: 1013-1019.PubMed Slivka SR, Loskutoff DJ: Platelets stimulate endothelial cells to synthesize type 1 plasminogen activator inhibitor. Evaluation of the role of transforming growth factor beta. Blood. 1991, 77: 1013-1019.PubMed
47.
go back to reference Jankun J, Aleem AM, Struniawski R, Lysiak-Szydlowska W, Selman SH, Skrzypczak-Jankun E: Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life. Pharmacol Rep. 2009, 61: 673-680.PubMedCrossRef Jankun J, Aleem AM, Struniawski R, Lysiak-Szydlowska W, Selman SH, Skrzypczak-Jankun E: Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life. Pharmacol Rep. 2009, 61: 673-680.PubMedCrossRef
48.
go back to reference Kupesiz A, Rajpurkar M, Warrier I, Hollon W, Tosun O, Lusher J, Chitlur M: Tissue plasminogen activator induced fibrinolysis: standardization of method using thromboelastography. Blood Coagul Fibrinolysis. 2010, 21: 320-324. 10.1097/MBC.0b013e32833464e9.PubMedCrossRef Kupesiz A, Rajpurkar M, Warrier I, Hollon W, Tosun O, Lusher J, Chitlur M: Tissue plasminogen activator induced fibrinolysis: standardization of method using thromboelastography. Blood Coagul Fibrinolysis. 2010, 21: 320-324. 10.1097/MBC.0b013e32833464e9.PubMedCrossRef
49.
go back to reference Mosesson MW: Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005, 3: 1894-1904. 10.1111/j.1538-7836.2005.01365.x.PubMedCrossRef Mosesson MW: Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005, 3: 1894-1904. 10.1111/j.1538-7836.2005.01365.x.PubMedCrossRef
50.
go back to reference Chajek T, Fainaru M: Behcet's disease with decreased fibrinolysis and superior vena caval occlusion. Br Med J. 1973, 1: 782-783. 10.1136/bmj.1.5856.782.PubMedCentralPubMedCrossRef Chajek T, Fainaru M: Behcet's disease with decreased fibrinolysis and superior vena caval occlusion. Br Med J. 1973, 1: 782-783. 10.1136/bmj.1.5856.782.PubMedCentralPubMedCrossRef
52.
go back to reference Haznedaroglu IC, Ozcebe O, Celik I, Dundar SV, Kirazhi S: Haemostatic markers of procoagulant imbalance in Behcet's disease. Eur J Haematol. 1996, 57: 107-108.PubMedCrossRef Haznedaroglu IC, Ozcebe O, Celik I, Dundar SV, Kirazhi S: Haemostatic markers of procoagulant imbalance in Behcet's disease. Eur J Haematol. 1996, 57: 107-108.PubMedCrossRef
53.
go back to reference Tauber H, Innerhofer P, Breitkopf R, Westermann I, Beer R, El Attal R, Strasak A, Mittermayr M: Prevalence and impact of abnormal ROTEM(R) assays in severe blunt trauma: results of the 'Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study'. Br J Anaesth. 2011, 107: 378-387. 10.1093/bja/aer158.PubMedCrossRef Tauber H, Innerhofer P, Breitkopf R, Westermann I, Beer R, El Attal R, Strasak A, Mittermayr M: Prevalence and impact of abnormal ROTEM(R) assays in severe blunt trauma: results of the 'Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study'. Br J Anaesth. 2011, 107: 378-387. 10.1093/bja/aer158.PubMedCrossRef
54.
go back to reference Bernhard H, Deutschmann A, Leschnik B, Schweintzger S, Novak M, Hauer A, Muntean W: Thrombin generation in pediatric patients with Crohn's disease. Inflamm Bowel Dis. 2011, 17: 2333-2339. 10.1002/ibd.21631.PubMedCrossRef Bernhard H, Deutschmann A, Leschnik B, Schweintzger S, Novak M, Hauer A, Muntean W: Thrombin generation in pediatric patients with Crohn's disease. Inflamm Bowel Dis. 2011, 17: 2333-2339. 10.1002/ibd.21631.PubMedCrossRef
55.
go back to reference Hayashi T, Sakurai Y, Fukuda K, Yada K, Ogiwara K, Matsumoto T, Yoshizawa H, Takahashi Y, Yoshikawa Y, Hayata Y: Correlations between global clotting function tests, duration of operation, and postoperative chest tube drainage in pediatric cardiac surgery. Paediatr Anaesth. 2011, 21: 865-871. 10.1111/j.1460-9592.2011.03524.x.PubMedCrossRef Hayashi T, Sakurai Y, Fukuda K, Yada K, Ogiwara K, Matsumoto T, Yoshizawa H, Takahashi Y, Yoshikawa Y, Hayata Y: Correlations between global clotting function tests, duration of operation, and postoperative chest tube drainage in pediatric cardiac surgery. Paediatr Anaesth. 2011, 21: 865-871. 10.1111/j.1460-9592.2011.03524.x.PubMedCrossRef
56.
go back to reference Haznedaroglu E, Karaaslan Y, Buyukasik Y, Kosar A, Ozcebe O, Haznedaroglu C, Kirazli E, Dundar SV: Selectin adhesion molecules in Behcet's disease. Ann Rheum Dis. 2000, 59: 61-63. 10.1136/ard.59.1.61.PubMedCentralPubMedCrossRef Haznedaroglu E, Karaaslan Y, Buyukasik Y, Kosar A, Ozcebe O, Haznedaroglu C, Kirazli E, Dundar SV: Selectin adhesion molecules in Behcet's disease. Ann Rheum Dis. 2000, 59: 61-63. 10.1136/ard.59.1.61.PubMedCentralPubMedCrossRef
57.
go back to reference Tayer-Shifman OE, Seyahi E, Nowatzky J, Ben-Chetrit E: Major vessel thrombosis in Behcet's disease: the dilemma of anticoagulant therapy - the approach of rheumatologists from different countries. Clin Exp Rheumatol. 2012, 30: 735-740.PubMed Tayer-Shifman OE, Seyahi E, Nowatzky J, Ben-Chetrit E: Major vessel thrombosis in Behcet's disease: the dilemma of anticoagulant therapy - the approach of rheumatologists from different countries. Clin Exp Rheumatol. 2012, 30: 735-740.PubMed
58.
go back to reference Uzun O, Akpolat T, Erkan L: Pulmonary vasculitis in behcet disease: a cumulative analysis. Chest. 2005, 127: 2243-2253. 10.1378/chest.127.6.2243.PubMedCrossRef Uzun O, Akpolat T, Erkan L: Pulmonary vasculitis in behcet disease: a cumulative analysis. Chest. 2005, 127: 2243-2253. 10.1378/chest.127.6.2243.PubMedCrossRef
59.
go back to reference Kahraman OC-OS, Kamali S: Proceedings of the American College of Rheumatology 67th Annual Scientific Meeting. Long-term course of deep venous thrombosis in patients with Behçet’s disease. Orlando, Florida New Jersey, USA: Wiley; 2003. Kahraman OC-OS, Kamali S: Proceedings of the American College of Rheumatology 67th Annual Scientific Meeting. Long-term course of deep venous thrombosis in patients with Behçet’s disease. Orlando, Florida New Jersey, USA: Wiley; 2003.
60.
go back to reference Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt GE: A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990, 322: 281-285. 10.1056/NEJM199002013220501.PubMedCrossRef Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt GE: A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990, 322: 281-285. 10.1056/NEJM199002013220501.PubMedCrossRef
Metadata
Title
Behçet’s disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity
Authors
Ihosvany Fernández-Bello
Francisco J López-Longo
Elena G Arias-Salgado
Víctor Jiménez-Yuste
Nora V Butta
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2013
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/1750-1172-8-81

Other articles of this Issue 1/2013

Orphanet Journal of Rare Diseases 1/2013 Go to the issue